We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Dermavant Sciences has signed a $160m revenue interest purchase and sale agreement for tapinarof with Marathon Asset Management, NovaQuest Capital Management and a third unnamed institutional investor in the US.
US Representative Elijah Cummings and Senator Bernie Sanders on Monday asked Marathon Pharmaceuticals to justify the list price of the recently approved Duchenne muscular dystrophy (DMD) drug Emflaza (deflazacort).